EVEREST MED (01952) announced the successful conclusion of its Special General Meeting held virtually on February 24, 2026, where all proposed resolutions were formally approved by shareholders. According to the announcement, the meeting approved, confirmed, and ratified the commercialization service agreement signed with HeSuan Biological on December 11, 2025, along with the related transactions contemplated under the agreement, providing support for the company's subsequent commercial operations and business advancement. Furthermore, the meeting approved resolutions concerning the grant of incentive arrangements to the company's management and the adoption of the 2026 Share Plan and its associated authorization limits. The strong approval for these resolutions reflects investor confidence in the company's strategic direction and corporate governance, and will support EVEREST MED in advancing its commercial layout and long-term development strategy. The company had previously stated that the collaboration with HeSuan Biological is expected to enhance the operational efficiency of its existing commercial platform and accelerate the development of full lifecycle and omnichannel capabilities for its products.